VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Sunday, January 11, 2026
Stock Comparison
AstraZeneca PLC vs Brown & Brown, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
AstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisBrown & Brown, Inc.
BRO · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Brown & Brown, Inc.'s moat claims, evidence, and risks.
View BRO analysisComparison highlights
- Moat score gap: AstraZeneca PLC leads (71 / 100 vs 61 / 100 for Brown & Brown, Inc.).
- Segment focus: AstraZeneca PLC has 6 segments (41% in Oncology); Brown & Brown, Inc. has 2 segments (59% in Retail).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Strong vs Moderate.
- Moat breadth: AstraZeneca PLC has 4 moat types across 3 domains; Brown & Brown, Inc. has 5 across 3.
Primary market context
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Brown & Brown, Inc.
Retail
Retail insurance brokerage and agency services (commercial P&C, employee benefits, personal lines) plus dealer F&I risk-mitigating products
Primarily United States; also selected international operations
Commercial (SMB to mid-market), public/quasi-public entities, professional and individual insured customers; auto/RV dealers for F&I
Insurance intermediary (agent/broker) and risk solutions advisor
59%
Side-by-side metrics
Moat coverage
Shared moat types
AstraZeneca PLC strengths
Brown & Brown, Inc. strengths
Segment mix
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Brown & Brown, Inc. segments
Full profile >Retail
Competitive
Specialty Distribution
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.